article thumbnail

Specialty pharma’s next big opportunity: it’s time for patient access to adopt an open protocol

pharmaphorum

The healthcare industry earnestly embarked on its first major digital transformation in the 1990s, when the large-scale transition to electronic recordkeeping began. healthcare facilities were found to have an EHR system fully implemented by 2004. This sector of the healthcare industry has both the incentive ?

article thumbnail

API nitrosamines: method sensitivity issues

European Pharmaceutical Review

European Directorate for the Quality of Medicines & HealthCare. Procedure under Article 5(3) of Regulation EC (No) 726/2004. Presented to: Prescription/Non-Prescription Stakeholder Forum November 19, 2020. N-Nitrosamines in active substances and revised sartan monographs. 2022 [cited 30 July 2022]. Assessment report.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

New Prescription Migraine Drugs Aren’t Resonating with Patients—Here’s How Pharma Can Boost Uptake

PM360

Despite a slew of prescription options and widespread advertising pushes, most patients are sticking with over-the-counter (OTC) remedies rather than trying new preventive medications, according to Phreesia Life Sciences’ survey results collected from more than 4,000 patients checking in for their doctors’ appointments in July 2021.

article thumbnail

Uri Goren

Cadensee

02:25 Uri Goren talks about his road to become a trailblazer and advocate for patient-centric healthcare. 52:21 Uri's opinion about the main problem that needs to be solved for the healthcare market with technology. When he was going through his cancer, he died in 2004. Interview Transcription (mild edits).

article thumbnail

Exforge antitrust settlement caps Novartis’ year of legal disputes

Pharmaceutical Technology

In 2020, the Federal Trade Commission issued a report regarding settlements reached between brand and generic manufacturers in FY 2017 and noted that “for the first time since [FY] 2004, no settlement agreement in [FY] 2017 contains a no-[authorized generic] AG commitment.”. Throughout 2022, Novartis was at the opposing ends of legal cases.